1iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) DeficiencyMay 7, 2024/in news, press release/by David AndersonMay 7, 2024
2iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.April 4, 2024/in news, press release/by David AndersonApril 4, 2024
3iECURE Secures Approval from U.K. Medicines & Healthcare Products Regulatory Agency to Expand the OTC-HOPE Study of ECUR-506March 5, 2024/in news, press release/by David AndersonMarch 6, 2024
4iECURE Secures Clearance from Australian Therapeutic Goods Administration for its Clinical Trial Approval for the OTC-HOPE Phase 1/2 Study of ECUR-506December 12, 2023/in news, press release/by eallisonDecember 13, 2023
5iECURE Appoints George Diaz, M.D., Ph.D., as VP, Therapeutic Area Lead for Urea Cycle DisordersApril 25, 2022/in news, press release/by David AndersonApril 25, 2022
6iECURE Expands Leadership Team with the Appointment of Mark Semanick as VP and Head of Technical Operations and Brad Dickerson as VP of Project Management & Patient AdvocacyFebruary 1, 2022/in news, press release/by David AndersonFebruary 1, 2022
